MCID: URT009
MIFTS: 17

Ureter Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Ureter Adenocarcinoma

MalaCards integrated aliases for Ureter Adenocarcinoma:

Name: Ureter Adenocarcinoma 12 14 69
Adenocarcinoma of Ureter 12
Ureteral Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4938
NCIt 47 C6155
UMLS 69 C1336873

Summaries for Ureter Adenocarcinoma

Disease Ontology : 12 An ureter carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Ureter Adenocarcinoma, also known as adenocarcinoma of ureter, is related to adenocarcinoma and papillary adenocarcinoma, and has symptoms including flank pain An important gene associated with Ureter Adenocarcinoma is CEACAM5 (Carcinoembryonic Antigen Related Cell Adhesion Molecule 5). The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lung and liver.

Related Diseases for Ureter Adenocarcinoma

Diseases related to Ureter Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 adenocarcinoma 9.7
2 papillary adenocarcinoma 9.7

Symptoms & Phenotypes for Ureter Adenocarcinoma

UMLS symptoms related to Ureter Adenocarcinoma:


flank pain

Drugs & Therapeutics for Ureter Adenocarcinoma

Drugs for Ureter Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
3 Adjuvants, Anesthesia Phase 3
4 Analgesics Phase 3
5 Analgesics, Opioid Phase 3
6 Anesthetics Phase 3
7 Anesthetics, General Phase 3
8 Anesthetics, Intravenous Phase 3
9 Central Nervous System Depressants Phase 3
10 Liver Extracts Phase 3,Phase 1
11 Narcotics Phase 3
12 Peripheral Nervous System Agents Phase 3
13 Cola Nutraceutical Phase 3,Phase 1
14
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
15
nivolumab Approved Phase 2,Phase 1 946414-94-4
16
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
17
Gemcitabine Approved Phase 2 95058-81-4 60750
18
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
21
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
22
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
23 Piritrexim Investigational Phase 2 72732-56-0
24
Camptothecin Experimental Phase 2 7689-03-4
25 Folic Acid Antagonists Phase 2
26 Vitamin B Complex Phase 2
27 Rubitecan Phase 2
28 topoisomerase I inhibitors Phase 2
29 Topoisomerase Inhibitors Phase 2
30 Albumin-Bound Paclitaxel Phase 2,Phase 1
31 Anti-Infective Agents Phase 2,Phase 1
32 Antimitotic Agents Phase 2,Phase 1
33 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
34 Immunosuppressive Agents Phase 2,Phase 1
35 Antibodies Phase 2,Phase 1
36 Antibodies, Monoclonal Phase 2,Phase 1
37 Immunoglobulins Phase 2,Phase 1
38 Antimetabolites Phase 2
39 Antimetabolites, Antineoplastic Phase 2
40 Antiviral Agents Phase 2
41 Micronutrients Phase 2
42 Nicotinic Acids Phase 2
43 Protein Kinase Inhibitors Phase 2
44 Trace Elements Phase 2
45 Vitamins Phase 2
46 Folate Nutraceutical Phase 2
47 Vitamin B9 Nutraceutical Phase 2
48 tyrosine Nutraceutical Phase 2
49 Vitamin B3 Nutraceutical Phase 2
50
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show all 20)

id Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
3 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
4 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
5 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
6 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03170960 Phase 1, Phase 2 cabozantinib;atezolizumab;cabozantinib
7 MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC) Recruiting NCT03015740 Phase 1, Phase 2 MGCD516;Nivolumab
8 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2 Cabozantinib
9 Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma Not yet recruiting NCT03274258 Phase 2 Nivolumab;Ipilimumab
10 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
11 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
12 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
13 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1 docetaxel;thalidomide
14 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
15 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
16 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Active, not recruiting NCT02443324 Phase 1 Ramucirumab;Pembrolizumab
17 Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757614
18 Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants Completed NCT00900276
19 Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction. Completed NCT00263107
20 Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers Recruiting NCT01846520

Search NIH Clinical Center for Ureter Adenocarcinoma

Genetic Tests for Ureter Adenocarcinoma

Anatomical Context for Ureter Adenocarcinoma

MalaCards organs/tissues related to Ureter Adenocarcinoma:

39
Endothelial, Lung, Liver, Kidney

Publications for Ureter Adenocarcinoma

Variations for Ureter Adenocarcinoma

Expression for Ureter Adenocarcinoma

Search GEO for disease gene expression data for Ureter Adenocarcinoma.

Pathways for Ureter Adenocarcinoma

GO Terms for Ureter Adenocarcinoma

Sources for Ureter Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....